126 related articles for article (PubMed ID: 23446656)
21. Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration - reply.
Achiron A
Acta Ophthalmol; 2015 Sep; 93(6):e508. PubMed ID: 25809013
[No Abstract] [Full Text] [Related]
22. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.
Weinberg DV; Shapiro H; Ehrlich JS
Ophthalmology; 2013 Jun; 120(6):1278-82. PubMed ID: 23453513
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
25. Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab.
de Geus SJ; Jager MJ; Luyten GP; Dijkman G
Acta Ophthalmol; 2013 Aug; 91(5):e411-3. PubMed ID: 23551594
[No Abstract] [Full Text] [Related]
26. The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery.
Jung JW; Chung BH; Kim EK; Seo KY; Kim TI
Yonsei Med J; 2015 Nov; 56(6):1671-7. PubMed ID: 26446653
[TBL] [Abstract][Full Text] [Related]
27. [Responses to ranibizumab in wet age-related macular degeneration patients with vitreomacular traction].
Filloy A; Arias L
Arch Soc Esp Oftalmol; 2013 Oct; 88(10):380-6. PubMed ID: 24060301
[TBL] [Abstract][Full Text] [Related]
28. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.
Johnson D; Sharma S
Curr Opin Ophthalmol; 2013 May; 24(3):205-12. PubMed ID: 23518613
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
Krebs I; Vécsei Marlovits V; Bodenstorfer J; Glittenberg C; Ansari Shahrezaei S; Ristl R; Binder S
Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
31. Quantitative assessment of central retinal thickness in recurrent neovascular age-related macular degeneration.
Chee Yee C; Papakostas TD; Vavvas DG
Br J Ophthalmol; 2014 Sep; 98(9):1308. PubMed ID: 24997184
[No Abstract] [Full Text] [Related]
32. Occurrence of macular hematoma after ranibizumab treatment for age-related macular degeneration.
Azar G; Mauget-Faÿsse M; Nyouma J; Cohen SY; Coscas F; Français-Maury C; Souied E; Soubrane G
Eur J Ophthalmol; 2015; 25(2):163-7. PubMed ID: 25684081
[TBL] [Abstract][Full Text] [Related]
33. In reply to the comment of Dr Asaf Achiron to a paper: Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration.
Kubicka-Trząska A; Wilańska J; Romanowska-Dixon B; Sanak M
Acta Ophthalmol; 2015 Sep; 93(6):e508-9. PubMed ID: 25988617
[No Abstract] [Full Text] [Related]
34. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
[TBL] [Abstract][Full Text] [Related]
35. Survey of Victorian ophthalmologists who use ranibizumab to treat age-related macular degeneration: to identify current practice and modifiable risk factors relevant to post-injection endophthalmitis.
Buck DA; Dawkins R; Kawasaki R; Sandhu SS; Allen PJ
Clin Exp Ophthalmol; 2015 Apr; 43(3):277-9. PubMed ID: 25112536
[No Abstract] [Full Text] [Related]
36. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
[TBL] [Abstract][Full Text] [Related]
37. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].
Cervera RE; Castro V; Montero J; Torralba C; Gracia A
Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436
[No Abstract] [Full Text] [Related]
38. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study.
Pinna A; Blasetti F; Ricci GD; Boscia F
Eur J Ophthalmol; 2017 May; 27(3):326-330. PubMed ID: 28009414
[TBL] [Abstract][Full Text] [Related]
39. Ranibizumab for age-related macular degeneration.
Cheng JW; Wei RL
N Engl J Med; 2011 Feb; 364(6):582. PubMed ID: 21306263
[No Abstract] [Full Text] [Related]
40. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration.
Ichiyama Y; Sawada T; Kakinoki M; Sawada O; Nakashima T; Saishin Y; Kawamura H; Ohji M
Ophthalmic Res; 2014; 52(4):234-8. PubMed ID: 25401265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
